Kaleido Biosciences

78 articles about Kaleido Biosciences

• 

  Kaleido Biosciences Culls Staff, Prepares to Cease Operations

  4/8/2022

  Shares of Kaleido Biosciences are plunging after the company announced its intentions to cease all company operations, lay off its remaining staff and delist from the Nasdaq Exchange.
• 

  ID’ing Exosites to Enable Specificity and Drug Intractable Targets

  2/14/2022

  Exo Therapeutics’ approach is not only different, it has revolutionary potential.
• 

  Gamida, Unity Layoffs Illustrate Challenges Faced by Small Biotech

  2/4/2022

  On Thursday, Unity Biotechnology announced that it is cutting 50% of its workforce, mainly in the research department.

• Kaleido Biosciences Announces Expansion of Collaboration with Janssen to Explore Potential of Microbiome Metabolic Therapies (MMT™) to Prevent Childhood-Onset of Atopic, Immune and Metabolic Conditions

  12/6/2021

  Kaleido Biosciences, Inc. today announced the extension and expansion of its research collaboration with Janssen Biotech, Inc. (“Janssen”).

• Kaleido Biosciences to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference

  11/15/2021

  Kaleido Biosciences, Inc., a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory conditions and diseases by selectively targeting the resident microbiome to restore gut-immune homeostasis, announced that CEO Dan Menichella will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference.

• Kaleido Biosciences to Appoint Dr. Alison Long as Chief Medical Officer

  11/10/2021

  Kaleido Biosciences, Inc. today announced the appointment of Alison Long, M.B.B.Ch., Ph.D., to its leadership team as Chief Medical Officer, effective December 15, 2021.

• Kaleido Biosciences Reports Third Quarter 2021 Financial Results

  11/1/2021

  Kaleido Biosciences, Inc. today reported financial results for the third quarter ended September 30, 2021.

• Kaleido Biosciences to Participate in the Jefferies Virtual Next Generation IBD Therapeutics Summit

  10/12/2021

  Kaleido Biosciences, Inc. today announced that CEO Dan Menichella will present a company overview at the Jefferies Virtual Next Generation IBD Therapeutics Summit at 1:45PM ET on Tuesday, October 19.

• Kaleido Biosciences Announces New Clinical and Preclinical Data Supporting Advancement of KB295 to a Phase 2 Clinical Study in Mild-to-Moderate Ulcerative Colitis

  10/5/2021

  Kaleido Biosciences, Inc. today announced topline data from the non-IND/CTA clinical study evaluating KB295, a novel Microbiome Metabolic Therapy (MMT™), in mild-to-moderate ulcerative colitis (UC).

• Kaleido Biosciences to Host Virtual R&D Presentation to Discuss Clinical Data and Pipeline Advancement on October 5, 2021

  9/29/2021

  Kaleido Biosciences, Inc. today announced that it will host a virtual R&D Presentation on October 5, 2021, at 8 a.m. ET.

• Kaleido Biosciences to Participate in the Morgan Stanley 19th Annual Virtual Global Healthcare Conference

  9/2/2021

  Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that CEO Dan Menichella will participate in a fireside chat at the Morgan Stanley 19th Annual Virtual Global Healthcare Conference.

• Kaleido Biosciences Reports Second Quarter 2021 Financial Results

  8/11/2021

  Kaleido Biosciences, Inc. today reported financial results for the second quarter ended June 30, 2021.

• Kaleido Biosciences and the COPD Foundation Announce a Strategic Collaboration to Advance KB109 into Phase 2 Clinical TrialOn track to initiate Phase 2 trial in the first quarter of 2022

  8/10/2021

  Kaleido Biosciences, Inc. today announced a strategic collaboration with the COPD Foundation to study KB109 in patients with chronic obstructive pulmonary disease (COPD).

• Kaleido Biosciences Announces New Chairperson Appointment to its Board of DirectorsCurrent Director Theo Melas-Kyriazi appointed Chairperson of the Board of Directors

  8/9/2021

  Kaleido Biosciences, Inc. today announced the appointment of current Board member Theo Melas-Kyriazi as Chairperson of the Board of Directors effective August 9, 2021.

• Kaleido Biosciences to Participate in the 41st Annual Canaccord Genuity Growth Conference

  8/6/2021

  Kaleido Biosciences, Inc. today announced that CFO William Duke will participate in a fireside chat at the Canaccord Genuity Growth Conference at 2:30PM ET on Thursday, August 12.

• Kaleido Biosciences to Participate in the JMP Securities Life Sciences Conference

  6/10/2021

  Kaleido Biosciences, Inc. today announced that CEO Dan Menichella will deliver a corporate presentation at the JMP Securities Life Sciences Conference at 4PM ET on Thursday, June 17.

• Kaleido Biosciences Reports First Quarter 2021 Financial Results

  5/4/2021

  --Positive results in patients with mild-to-moderate COVID-19 demonstrate KB109’s potential to reduce healthcare utilization and recovery time; initiating IND application to support further development-- --Topline data from a clinical study of KB295 in patients with mild-to-moderate ulcerative colitis on track for mid-2021--

• Kaleido Biosciences Announces Collaboration with Robert Jenq, M.D., to Explore Potential of its Microbiome Metabolic Therapies (MMT™) in Preventing Febrile Neutropenia

  4/20/2021

  Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a small molecule driven approach to targeting the microbiome to treat disease and improve human health, today announced a research collaboration with researcher Robert Jenq, M.D. Professor of Genomic Medicine, at The University of Texas MD Anderson Cancer Center

• Kaleido Biosciences to Participate in Jefferies Microbiome-Based Therapeutics Summit

  4/15/2021

  Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that CEO Dan Menichella will participate in an analyst-led fireside chat on Thursday, April 22 at the Jefferies Microbiome-Based Therapeutics Summit.

• 

  Clinical Catch-Up: March 22-26

  3/29/2021

  There was a fair amount of clinical trial news last week. Here’s a look.